| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.883 | 0.002 | 0.883 | 5 Hydroxytryptamine 3 antagonist | 0.72 0.002 DBMET00406 0.61 0.002 DBMET00407 | ||
| 0.679 | 0.001 | 0.679 | 5 Hydroxytryptamine 3A agonist | 0.556 0.001 DBMET00406 0.467 0.002 DBMET00407 | ||
| 0.664 | 0.001 | 0.664 | 5 Hydroxytryptamine 3A antagonist | 0.457 0.002 DBMET00406 0.258 0.003 DBMET00407 | ||
| 0.523 | 0.006 | 0.523 | 5 Hydroxytryptamine antagonist | 0.318 0.017 DBMET00406 0.348 0.014 DBMET00407 | ||
| 0.551 | 0.036 | 0.551 | Analgesic | 0.306 0.137 DBMET00406 0.51 0.046 DBMET00407 | ||
| 0.501 | 0.02 | 0.501 | Nootropic | 0.436 0.03 DBMET00406 0.291 0.079 DBMET00407 | ||
| 0.407 | 0.027 | 0.407 | HERG channel blocker | 0.274 0.057 DBMET00406 0.144 0.136 DBMET00407 | ||
| 0.321 | 0.003 | 0.321 | 5 Hydroxytryptamine 3 agonist | 0.2 0.004 DBMET00406 0.144 0.005 DBMET00407 | ||
| 0.351 | 0.036 | 0.351 | Potassium channel (Voltage-sensitive) blocker | 0.225 0.08 DBMET00406 | ||
| 0.321 | 0.008 | 0.321 | Polo-like kinase-3 inhibitor | 0.273 0.017 DBMET00406 0.277 0.016 DBMET00407 | ||
| 0.359 | 0.05 | 0.359 | Spasmolytic | 0.305 0.068 DBMET00406 0.327 0.06 DBMET00407 | ||
| 0.303 | 0.003 | 0.303 | 5 Hydroxytryptamine 3B antagonist | 0.288 0.003 DBMET00406 0.089 0.005 DBMET00407 | ||
| 0.331 | 0.032 | 0.339 | 5 Hydroxytryptamine uptake stimulant | 0.339 0.029 DBMET00406 0.336 0.03 DBMET00407 | DBMET00406 | |
| 0.302 | 0.005 | 0.497 | Acetylcholine agonist | 0.497 0.003 DBMET00406 0.174 0.019 DBMET00407 | DBMET00406 | |
| 0.317 | 0.021 | 0.317 | 5 Hydroxytryptamine 1E antagonist | 0.294 0.033 DBMET00406 0.283 0.042 DBMET00407 | ||
| 0.363 | 0.076 | 0.363 | Toll-Like receptor 7 agonist | 0.349 0.082 DBMET00407 | ||
| 0.283 | 0.004 | 0.674 | Acetylcholine nicotinic agonist | 0.674 0.002 DBMET00406 0.196 0.008 DBMET00407 | DBMET00406 | |
| 0.356 | 0.079 | 0.356 | Toll-Like receptor agonist | 0.342 0.086 DBMET00407 | ||
| 0.265 | 0.01 | 0.265 | 5 Hydroxytryptamine agonist | 0.176 0.017 DBMET00406 0.135 0.024 DBMET00407 | ||
| 0.248 | 0.006 | 0.248 | Hematopoietic | 0.107 0.03 DBMET00406 0.132 0.018 DBMET00407 | ||
| 0.246 | 0.008 | 0.33 | Cyclin A2 inhibitor | 0.33 0.005 DBMET00406 0.129 0.017 DBMET00407 | DBMET00406 | |
| 0.312 | 0.076 | 0.312 | Immunomodulator | 0.203 0.16 DBMET00406 0.188 0.179 DBMET00407 | ||
| 0.229 | 0.008 | 0.338 | Cyclin A inhibitor | 0.338 0.005 DBMET00406 0.117 0.018 DBMET00407 | DBMET00406 | |
| 0.218 | 0.003 | 0.687 | Nicotinic alpha7 receptor agonist | 0.687 0.002 DBMET00406 0.112 0.007 DBMET00407 | DBMET00406 | |
| 0.215 | 0.004 | 0.625 | Nicotinic neuronal receptor agonist | 0.625 0.002 DBMET00406 0.108 0.011 DBMET00407 | DBMET00406 | |
| 0.209 | 0.007 | 0.209 | Cannabinoid receptor agonist | 0.059 0.049 DBMET00407 | ||
| 0.187 | 0.003 | 0.187 | 5 Hydroxytryptamine 4 antagonist | 0.139 0.004 DBMET00406 0.154 0.004 DBMET00407 | ||
| 0.247 | 0.068 | 0.247 | Potassium channel blocker | |||
| 0.188 | 0.012 | 0.188 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.158 0.019 DBMET00406 0.104 0.042 DBMET00407 | ||
| 0.176 | 0.01 | 0.176 | Polo-like kinase-1 inhibitor | 0.164 0.013 DBMET00406 0.146 0.018 DBMET00407 | ||
| 0.2 | 0.035 | 0.229 | Cyclin-dependent kinase 8 inhibitor | 0.229 0.022 DBMET00406 0.132 0.101 DBMET00407 | DBMET00406 | |
| 0.161 | 0.004 | 0.161 | Polo-like kinase-2 inhibitor | 0.132 0.005 DBMET00406 0.136 0.005 DBMET00407 | ||
| 0.15 | 0.006 | 0.156 | Dopamine transporter inhibitor | 0.156 0.005 DBMET00406 0.117 0.009 DBMET00407 | DBMET00406 | |
| 0.154 | 0.01 | 0.154 | Cannabinoid CB1 receptor agonist | 0.058 0.045 DBMET00406 | ||
| 0.276 | 0.134 | 0.276 | Antiobesity | 0.222 0.185 DBMET00406 | ||
| 0.188 | 0.058 | 0.188 | Antipruritic | 0.14 0.107 DBMET00407 | ||
| 0.144 | 0.028 | 0.221 | CDK2/cyclin A inhibitor | 0.221 0.011 DBMET00406 0.116 0.045 DBMET00407 | DBMET00406 | |
| 0.139 | 0.025 | 0.139 | Acetylcholine release stimulant | 0.112 0.063 DBMET00406 0.103 0.08 DBMET00407 | ||
| 0.114 | 0.002 | 0.114 | 5 Hydroxytryptamine 4 agonist | 0.082 0.003 DBMET00406 0.045 0.004 DBMET00407 | ||
| 0.134 | 0.029 | 0.134 | Interleukin 2 antagonist | 0.104 0.08 DBMET00407 | ||
| 0.112 | 0.008 | 0.112 | Orexin receptor antagonist | 0.077 0.031 DBMET00406 | ||
| 0.156 | 0.053 | 0.345 | Cyclin-dependent kinase inhibitor | 0.345 0.015 DBMET00406 | DBMET00406 | |
| 0.118 | 0.024 | 0.118 | Bromodomain-containing protein 2 inhibitor | |||
| 0.095 | 0.008 | 0.095 | Lysine-specific demethylase 1A inhibitor | 0.087 0.01 DBMET00406 0.064 0.024 DBMET00407 | ||
| 0.13 | 0.044 | 0.214 | Protein kinase C gamma inhibitor | 0.214 0.011 DBMET00406 | DBMET00406 | |
| 0.102 | 0.017 | 0.102 | Acetylcholine muscarinic agonist | 0.077 0.024 DBMET00406 | ||
| 0.097 | 0.015 | 0.132 | Protein kinase C beta inhibitor | 0.132 0.005 DBMET00406 | DBMET00406 | |
| 0.093 | 0.013 | 0.093 | Acetylcholine M1 receptor agonist | 0.076 0.017 DBMET00406 | ||
| 0.131 | 0.052 | 0.131 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.089 | 0.01 | 0.129 | Cyclin A1 inhibitor | 0.129 0.005 DBMET00406 0.062 0.034 DBMET00407 | DBMET00406 | |
| 0.094 | 0.017 | 0.094 | Orexin receptor 1 antagonist | 0.082 0.032 DBMET00406 | ||
| 0.12 | 0.052 | 0.293 | Cyclin-dependent kinase 2 inhibitor | 0.293 0.013 DBMET00406 | DBMET00406 | |
| 0.134 | 0.071 | 0.134 | Sodium channel blocker | |||
| 0.078 | 0.018 | 0.078 | Phosphodiesterase 1A inhibitor | |||
| 0.164 | 0.104 | 0.168 | Psychostimulant | 0.168 0.101 DBMET00407 | DBMET00407 | |
| 0.152 | 0.093 | 0.341 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.341 0.021 DBMET00406 | DBMET00406 | |
| 0.081 | 0.021 | 0.097 | Cyclin-dependent kinase 6 inhibitor | 0.097 0.011 DBMET00406 | DBMET00406 | |
| 0.072 | 0.013 | 0.093 | Cyclin D3 inhibitor | 0.093 0.008 DBMET00406 0.05 0.021 DBMET00407 | DBMET00406 | |
| 0.154 | 0.095 | 0.251 | ATPase inhibitor | 0.251 0.013 DBMET00406 0.163 0.08 DBMET00407 | DBMET00406 | |
| 0.086 | 0.03 | 0.086 | Dopamine D3 antagonist | 0.056 0.049 DBMET00406 | ||
| 0.082 | 0.026 | 0.087 | Adrenaline uptake inhibitor | 0.087 0.023 DBMET00406 0.059 0.045 DBMET00407 | DBMET00406 | |
| 0.099 | 0.045 | 0.099 | Phosphodiesterase I inhibitor | |||
| 0.071 | 0.017 | 0.071 | Chemokine receptor agonist | 0.067 0.021 DBMET00406 | ||
| 0.064 | 0.011 | 0.064 | Somatostatin 4 agonist | 0.034 0.03 DBMET00407 | ||
| 0.074 | 0.022 | 0.074 | Melanin-concentrating hormone receptor 1 antagonist | 0.058 0.031 DBMET00406 | ||
| 0.072 | 0.021 | 0.072 | Ca(v)3.2 blocker | |||
| 0.064 | 0.016 | 0.064 | Phosphodiesterase 7A inhibitor | 0.048 0.045 DBMET00406 0.054 0.032 DBMET00407 | ||
| 0.066 | 0.024 | 0.076 | Nicotinic receptor alpha7 subunit antagonist | 0.076 0.018 DBMET00406 | DBMET00406 | |
| 0.08 | 0.039 | 0.08 | Phosphodiesterase 5A inhibitor | |||
| 0.108 | 0.07 | 0.18 | Activin receptor-like kinase 4 inhibitor | 0.18 0.018 DBMET00406 0.097 0.092 DBMET00407 | DBMET00406 | |
| 0.122 | 0.084 | 0.172 | Tyrosine-protein kinase receptor antagonist | 0.172 0.053 DBMET00406 | DBMET00406 | |
| 0.132 | 0.094 | 0.156 | Cholinergic | 0.156 0.072 DBMET00406 | DBMET00406 | |
| 0.079 | 0.042 | 0.079 | Phosphodiesterase V inhibitor | |||
| 0.098 | 0.061 | 0.114 | Creatine kinase inhibitor | 0.114 0.045 DBMET00407 | DBMET00407 | |
| 0.144 | 0.107 | 0.241 | TRKC antagonist | 0.241 0.051 DBMET00406 | DBMET00406 | |
| 0.057 | 0.024 | 0.057 | Bromodomain-containing protein 3 inhibitor | |||
| 0.067 | 0.034 | 0.067 | Phosphodiesterase 1B inhibitor | |||
| 0.117 | 0.085 | 0.117 | Phosphodiesterase inhibitor | |||
| 0.072 | 0.042 | 0.072 | Acetylcholine M5 receptor agonist | |||
| 0.078 | 0.049 | 0.078 | Acetylcholine M4 receptor antagonist | |||
| 0.108 | 0.079 | 0.156 | TRKA antagonist | 0.156 0.047 DBMET00406 | DBMET00406 | |
| 0.11 | 0.082 | 0.11 | Protein kinase (CK1) delta inhibitor | |||
| 0.068 | 0.04 | 0.068 | 5 Hydroxytryptamine uptake inhibitor | 0.068 0.04 DBMET00406 | ||
| 0.071 | 0.043 | 0.071 | Phosphodiesterase 4B inhibitor | |||
| 0.06 | 0.032 | 0.06 | Bromodomain-containing protein 4 inhibitor | |||
| 0.064 | 0.037 | 0.064 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.066 | 0.039 | 0.066 | Phosphodiesterase VII inhibitor | |||
| 0.041 | 0.015 | 0.041 | CXC chemokine receptor agonist | 0.038 0.018 DBMET00406 | ||
| 0.058 | 0.035 | 0.058 | Cannabinoid CB2 receptor agonist | |||
| 0.056 | 0.033 | 0.056 | Cannabinoid CB2 receptor antagonist | 0.046 0.039 DBMET00407 | ||
| 0.214 | 0.191 | 0.214 | GABA C receptor rho-3 antagonist | |||
| 0.15 | 0.128 | 0.359 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.359 0.021 DBMET00406 | DBMET00406 | |
| 0.092 | 0.07 | 0.092 | Sphingomyelinase inhibitor | |||
| 0.155 | 0.133 | 0.155 | Histone acetyltransferase inhibitor | |||
| 0.062 | 0.04 | 0.064 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.064 0.036 DBMET00407 | DBMET00407 | |
| 0.07 | 0.049 | 0.07 | Cannabinoid receptor antagonist | |||
| 0.048 | 0.027 | 0.048 | Baculoviral IAP repeat-containing protein inhibitor | |||
| 0.072 | 0.052 | 0.095 | Dopamine antagonist | 0.095 0.041 DBMET00406 | DBMET00406 | |
| 0.095 | 0.074 | 0.095 | Hedgehog signaling inhibitor | |||
| 0.084 | 0.064 | 0.092 | Opioid antagonist | 0.079 0.07 DBMET00406 0.092 0.054 DBMET00407 | DBMET00407 | |
| 0.023 | 0.005 | 0.023 | Complement factor D inhibitor | |||
| 0.09 | 0.074 | 0.09 | Chemokine receptor antagonist | |||
| 0.053 | 0.036 | 0.053 | Dipeptidyl peptidase inhibitor | 0.049 0.046 DBMET00406 | ||
| 0.122 | 0.106 | 0.142 | Acetylcholine M1 receptor antagonist | 0.142 0.083 DBMET00407 | DBMET00407 | |
| 0.031 | 0.017 | 0.043 | CDK4/cyclin D3 inhibitor | 0.043 0.009 DBMET00406 | DBMET00406 | |
| 0.036 | 0.021 | 0.036 | Carnitine palmitoyltransferase 1 inhibitor | |||
| 0.055 | 0.042 | 0.058 | Fatty acid synthase inhibitor | 0.058 0.038 DBMET00406 | DBMET00406 | |
| 0.034 | 0.023 | 0.034 | Carnitine palmitoyltransferase inhibitor | |||
| 0.059 | 0.05 | 0.059 | Phosphodiesterase 1C inhibitor | |||
| 0.059 | 0.05 | 0.059 | 5 Hydroxytryptamine 1D antagonist | |||
| 0.108 | 0.1 | 0.108 | Sodium channel (voltage-gated) blocker | |||
| 0.035 | 0.027 | 0.035 | Orexin receptor 2 antagonist | |||
| 0.183 | 0.175 | 0.183 | Gastrin inhibitor | |||
| 0.028 | 0.021 | 0.028 | Carnitine palmitoyltransferase 1A inhibitor | |||
| 0.095 | 0.089 | 0.095 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.029 | 0.023 | 0.029 | Acetylcholine M4 receptor agonist | 0.028 0.024 DBMET00406 | ||
| 0.032 | 0.027 | 0.032 | Protein kinase C beta I inhibitor | |||
| 0.056 | 0.051 | 0.095 | Tyk2 inhibitor | 0.095 0.03 DBMET00406 | DBMET00406 | |
| 0.26 | 0.256 | 0.358 | Antiinflammatory | 0.358 0.167 DBMET00407 | DBMET00407 | |
| 0.046 | 0.042 | 0.048 | Nicotinic receptor alpha4 subunit antagonist | 0.048 0.037 DBMET00406 | DBMET00406 | |
| 0.009 | 0.007 | 0.009 | Baculoviral IAP repeat-containing protein 2 inhibitor | |||
| 0.036 | 0.035 | 0.036 | Smo receptor antagonist | |||
| 0.069 | 0.077 | 0.081 | Opioid kappa receptor antagonist | 0.081 0.057 DBMET00407 | DBMET00407 | |
| 0.07 | 0.08 | 0.147 | CDK/cyclin complex inhibitor | 0.147 0.031 DBMET00406 | DBMET00406 | |
| 0.045 | 0.057 | 0.077 | Pim-2 kinase inhibitor | 0.077 0.022 DBMET00406 | DBMET00406 | |
| 0.075 | 0.091 | 0.133 | Bronchodilator | 0.133 0.038 DBMET00407 | DBMET00407 | |
| 0.076 | 0.098 | 0.135 | Protein kinase C zeta inhibitor | 0.135 0.025 DBMET00406 | DBMET00406 | |
| 0.048 | 0.075 | 0.088 | Neuronal nicotinic receptor antagonist | 0.088 0.03 DBMET00406 | DBMET00406 | |
| 0.07 | 0.099 | 0.101 | Prolactin inhibitor | 0.101 0.054 DBMET00406 | DBMET00406 | |
| 0.083 | 0.114 | 0.103 | Acetylcholine muscarinic antagonist | 0.103 0.087 DBMET00407 | DBMET00407 | |
| 0.076 | 0.108 | 0.271 | Polo-like kinase-4 inhibitor | 0.271 0.006 DBMET00406 | DBMET00406 | |
| 0.049 | 0.082 | 0.078 | CDK1/cyclin B1 inhibitor | 0.078 0.04 DBMET00406 | DBMET00406 | |
| 0.106 | 0.142 | 0.242 | Heat shock protein 90 antagonist | 0.179 0.05 DBMET00406 0.242 0.023 DBMET00407 | DBMET00407 | |
| 0.029 | 0.066 | 0.049 | Nicotinic receptor alpha3 subunit antagonist | 0.049 0.026 DBMET00406 | DBMET00406 | |
| 0.208 | 0.254 | 0.432 | MAP kinase kinase 6 inhibitor | 0.432 0.042 DBMET00406 | DBMET00406 | |
| 0.066 | 0.117 | 0.076 | MAP kinase 7 inhibitor | 0.076 0.059 DBMET00406 | DBMET00406 | |
| 0.112 | 0.162 | 0.137 | MAP kinase 3 inhibitor | 0.137 0.091 DBMET00406 | DBMET00406 | |
| 0.076 | 0.129 | 0.093 | mTOR complex 1 inhibitor | 0.093 0.079 DBMET00406 | DBMET00406 | |
| 0.05 | 0.104 | 0.164 | Protein kinase B gamma inhibitor | 0.164 0.013 DBMET00406 | DBMET00406 | |
| 0.014 | 0.068 | 0.024 | 5 Hydroxytryptamine 1F agonist | 0.024 0.02 DBMET00406 | DBMET00406 | |
| 0.063 | 0.118 | 0.111 | Pim-3 kinase inhibitor | 0.111 0.036 DBMET00406 | DBMET00406 | |
| 0.052 | 0.107 | 0.084 | Acetylcholine nicotinic antagonist | 0.084 0.051 DBMET00406 | DBMET00406 | |
| 0.077 | 0.134 | 0.201 | Cyclin-dependent kinase 7 inhibitor | 0.201 0.033 DBMET00406 | DBMET00406 | |
| 0.161 | 0.223 | 0.182 | Tyrosine 3 hydroxylase inhibitor | 0.182 0.172 DBMET00406 | DBMET00406 | |
| 0.026 | 0.088 | 0.082 | Dopamine D4 antagonist | 0.082 0.032 DBMET00406 | DBMET00406 | |
| 0.063 | 0.126 | 0.172 | Cyclin-dependent kinase 5 inhibitor | 0.172 0.03 DBMET00406 | DBMET00406 | |
| 0.065 | 0.129 | 0.086 | Cyclin-dependent kinase 9 inhibitor | 0.086 0.081 DBMET00406 | DBMET00406 | |
| 0.029 | 0.097 | 0.1 | Tyrosine-protein kinase EMT inhibitor | 0.1 0.018 DBMET00406 | DBMET00406 | |
| 0.09 | 0.16 | 0.372 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.372 0.022 DBMET00406 | DBMET00406 | |
| 0.056 | 0.126 | 0.075 | GABA A receptor agonist | 0.075 0.074 DBMET00406 | DBMET00406 | |
| 0.042 | 0.113 | 0.064 | Protein kinase C alpha inhibitor | 0.064 0.053 DBMET00406 | DBMET00406 | |
| 0.008 | 0.08 | 0.047 | Acetyl-CoA carboxylase 1 inhibitor | 0.047 0.006 DBMET00407 | DBMET00407 | |
| 0.055 | 0.132 | 0.122 | Pim-1 kinase inhibitor | 0.122 0.041 DBMET00406 | DBMET00406 | |
| 0.064 | 0.15 | 0.133 | MAP kinase 13 inhibitor | 0.133 0.046 DBMET00406 | DBMET00406 | |
| 0.089 | 0.181 | 0.23 | Protein kinase (CK1) gamma 3 inhibitor | 0.23 0.033 DBMET00406 | DBMET00406 | |
| 0.03 | 0.132 | 0.089 | Cyclin-dependent kinase 4 inhibitor | 0.089 0.03 DBMET00406 | DBMET00406 | |
| 0.145 | 0.25 | 0.232 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.232 0.124 DBMET00406 | DBMET00406 | |
| 0.05 | 0.158 | 0.127 | Protein kinase (CK2) alpha inhibitor | 0.127 0.057 DBMET00406 | DBMET00406 | |
| 0.044 | 0.153 | 0.092 | MAP kinase kinase 8 inhibitor | 0.092 0.026 DBMET00406 | DBMET00406 | |
| 0.033 | 0.143 | 0.187 | CDK2/cyclin E2 inhibitor | 0.187 0.012 DBMET00406 | DBMET00406 | |
| 0.041 | 0.155 | 0.165 | Protein kinase A inhibitor | 0.165 0.021 DBMET00406 | DBMET00406 | |
| 0.038 | 0.161 | 0.136 | Aurora-A kinase inhibitor | 0.136 0.046 DBMET00406 | DBMET00406 | |
| 0.026 | 0.152 | 0.065 | CDC7 inhibitor | 0.065 0.049 DBMET00406 | DBMET00406 | |
| 0.084 | 0.213 | 0.224 | EphB2 antagonist | 0.224 0.072 DBMET00406 | DBMET00406 | |
| 0.015 | 0.146 | 0.053 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.053 0.016 DBMET00406 | DBMET00406 | |
| 0.178 | 0.31 | 0.343 | Cyclophilin D inhibitor | 0.343 0.128 DBMET00407 | DBMET00407 | |
| 0.099 | 0.235 | 0.335 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.335 0.029 DBMET00406 | DBMET00406 | |
| 0.028 | 0.167 | 0.114 | Check point kinase 1 inhibitor | 0.114 0.023 DBMET00406 | DBMET00406 | |
| 0.046 | 0.188 | 0.101 | Aurora-B kinase inhibitor | 0.101 0.081 DBMET00406 | DBMET00406 | |
| 0.045 | 0.188 | 0.231 | Glycogen synthase kinase-3 inhibitor | 0.231 0.025 DBMET00406 | DBMET00406 | |
| 0.035 | 0.181 | 0.083 | Protein kinase (CK2) inhibitor | 0.083 0.079 DBMET00406 | DBMET00406 | |
| 0.106 | 0.254 | 0.152 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.152 0.13 DBMET00406 | DBMET00406 | |
| 0.042 | 0.192 | 0.21 | Glycogen synthase kinase-3 beta inhibitor | 0.21 0.026 DBMET00406 | DBMET00406 | |
| 0.176 | 0.33 | 0.416 | MAP kinase 1 inhibitor | 0.416 0.097 DBMET00406 | DBMET00406 | |
| 0.018 | 0.174 | 0.055 | Poly(ADP-ribose) polymerase inhibitor | 0.055 0.02 DBMET00406 | DBMET00406 | |
| 0.032 | 0.193 | 0.081 | Fibroblast growth factor 1 antagonist | 0.081 0.073 DBMET00406 | DBMET00406 | |
| 0.026 | 0.188 | 0.117 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.117 0.028 DBMET00406 | DBMET00406 | |
| 0.031 | 0.2 | 0.164 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.164 0.048 DBMET00406 | DBMET00406 | |
| 0.004 | 0.178 | 0.022 | Acetyl-CoA carboxylase 2 inhibitor | 0.022 0.016 DBMET00407 | DBMET00407 | |
| 0.055 | 0.229 | 0.19 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.19 0.049 DBMET00406 | DBMET00406 | |
| 0.177 | 0.351 | 0.251 | 5 Hydroxytryptamine release inhibitor | 0.251 0.227 DBMET00406 | DBMET00406 | |
| 0.04 | 0.221 | 0.11 | Protein kinase C mu inhibitor | 0.11 0.049 DBMET00406 | DBMET00406 | |
| 0.027 | 0.21 | 0.122 | Cyclin-dependent kinase 1 inhibitor | 0.122 0.054 DBMET00406 | DBMET00406 | |
| 0.028 | 0.226 | 0.16 | Rho-associated kinase II inhibitor | 0.16 0.016 DBMET00406 | DBMET00406 | |
| 0.075 | 0.29 | 0.196 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.196 0.077 DBMET00406 | DBMET00406 | |
| 0.055 | 0.271 | 0.153 | Protein kinase (CK1) gamma 1 inhibitor | 0.153 0.066 DBMET00406 | DBMET00406 | |
| 0.013 | 0.234 | 0.056 | Acetyl-CoA carboxylase inhibitor | 0.056 0.017 DBMET00407 | DBMET00407 | |
| 0.039 | 0.277 | 0.193 | Ribosomal protein S6 kinase inhibitor | 0.193 0.04 DBMET00406 | DBMET00406 | |
| 0.031 | 0.27 | 0.097 | MAP kinase 8 inhibitor | 0.097 0.063 DBMET00406 | DBMET00406 | |
| 0.079 | 0.319 | 0.146 | Focal adhesion kinase 2 inhibitor | 0.146 0.137 DBMET00406 | DBMET00406 | |
| 0.019 | 0.266 | 0.083 | Rho-associated kinase I inhibitor | 0.083 0.043 DBMET00406 | DBMET00406 | |
| 0.063 | 0.313 | 0.322 | Death-associated protein kinase 3 inhibitor | 0.322 0.032 DBMET00406 | DBMET00406 | |
| 0.039 | 0.29 | 0.168 | Protein kinase (CK1) gamma inhibitor | 0.168 0.058 DBMET00406 | DBMET00406 | |
| 0.043 | 0.297 | 0.198 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.198 0.078 DBMET00406 | DBMET00406 | |
| 0.023 | 0.277 | 0.061 | MAP kinase kinase 10 inhibitor | 0.061 0.056 DBMET00406 | DBMET00406 | |
| 0.008 | 0.267 | 0.058 | Cyclin E inhibitor | 0.058 0.042 DBMET00406 | DBMET00406 | |
| 0.038 | 0.308 | 0.127 | Protein kinase (CK1) gamma 2 inhibitor | 0.127 0.06 DBMET00406 | DBMET00406 | |
| 0.14 | 0.423 | 0.237 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.237 0.084 DBMET00406 | DBMET00406 | |
| 0.033 | 0.32 | 0.2 | CDC-like kinase 2 inhibitor | 0.2 0.067 DBMET00406 | DBMET00406 | |
| 0.049 | 0.344 | 0.156 | MAP kinase kinase 2 inhibitor | 0.156 0.116 DBMET00406 | DBMET00406 | |
| 0.131 | 0.427 | 0.225 | MAP kinase kinase 3 inhibitor | 0.225 0.064 DBMET00406 | DBMET00406 | |
| 0.017 | 0.319 | 0.119 | Rho-associated kinase inhibitor | 0.119 0.027 DBMET00406 | DBMET00406 | |
| 0.015 | 0.322 | 0.097 | Check point kinase 2 inhibitor | 0.097 0.068 DBMET00406 | DBMET00406 | |
| 0.023 | 0.332 | 0.097 | Protein kinase C delta inhibitor | 0.097 0.055 DBMET00406 | DBMET00406 | |
| 0.033 | 0.348 | 0.18 | Protein kinase C nu inhibitor | 0.18 0.055 DBMET00406 | DBMET00406 | |
| 0.028 | 0.37 | 0.132 | Clk dual-specificity kinase inhibitor | 0.132 0.131 DBMET00406 | DBMET00406 | |
| 0.042 | 0.423 | 0.181 | CDK3/cyclin E inhibitor | 0.181 0.012 DBMET00406 | DBMET00406 | |
| 0.053 | 0.452 | 0.138 | CF transmembrane conductance regulator agonist | 0.138 0.1 DBMET00406 | DBMET00406 | |
| 0.069 | 0.47 | 0.173 | MAP-kinase-activated kinase 5 inhibitor | 0.173 0.144 DBMET00406 | DBMET00406 | |
| 0.022 | 0.454 | 0.278 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.278 0.031 DBMET00406 | DBMET00406 | |
| 0.061 | 0.516 | 0.162 | Death-associated protein kinase 2 inhibitor | 0.162 0.081 DBMET00406 | DBMET00406 | |
| 0.043 | 0.523 | 0.146 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.146 0.081 DBMET00406 | DBMET00406 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |